Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-like protein 3 (Alp3) is a surface-anchored protein belonging to the alpha-like protein (Alp) family of Streptococcus agalactiae (Group B Streptococcus, GBS). It is a chimeric molecule characterized by a mosaic structure of repetitive domains shared with other family members such as Alpha C and Rib. Alp3 is a key virulence factor that facilitates bacterial adherence to and invasion of host epithelial cells, particularly within the vaginal and cervical mucosa, which is critical for maternal colonization and subsequent neonatal infection. It is also expressed by Streptococcus pyogenes (Group A Streptococcus), where it is commonly referred to as R28. As a highly immunogenic surface antigen, Alp3 is a major target in the development of maternal vaccines designed to provide passive immunity to newborns against GBS-induced sepsis, meningitis, and pneumonia.
Induction of protective opsonophagocytic antibodies that prevent bacterial adherence and promote immune clearance.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-like protein 3 (Alp3) (Alp3).